3:30pm Chair Introduction

Sven Kili, Chief Executive Officer, Antion Biosciences

3:35pm Presentation: Commercially Conscious Development: A Necessity in Today’s Biotech Market

• Why it is critical in this market to consider commercialization in early stages of development
• What are some of the key considerations that will make the most impact

Jennifer Chow, Chief Executive Officer, Chimeric Therapeutics

3:50pm Presentation: Risk Mitigation Strategies for Making your CGT Venture More Attractive to Investors

• Indication choice – choosing the ‘market’
• Clinical trial design – safety and efficacy data
• Requirements for Final Therapeutic Product & Target Product Profiles
• Application of Quality by Design (regressive and progressive planning with the final therapeutic product in mind)
• Importance of Cross-Functional Teams and selection of a de-risked plan
• Company-investor matching. Importance of seeing investor as ‘one of the team’ and not a ‘means to an end’
• Joining Standardization Groups like ISCBI, GAiT and ISCT assist in derisking

Stephen Sullivan, Founder, Lindville Bio

3:35pm Presentation: Advice for Startups in the New Normal – Best Practices to Secure the Right Funding & Thrive

Daniella Kranjac, Founding Partner, Dynamk Capital

4:05pm Presentation: Working with Pharma to Advance Cell Therapies from Corporate Venture Investment to Partnering

• What is pharma looking for in cell therapy deals
• What are the key issues, challenges?
• What are the key investment themes for pharma partners

Konstantina Katcheves, Senior Vice President Business Development, Bristol Myers Squibb

4:20pm Closing Panel with Q&A

With all session participants, joined by:

Miguel Forte, President-Elect, International Society for Cell & Gene Therapy

Jacob Becraft, CEO, Strand Therapeutics